Abstract:
A digital fluorographic method and system calls for digitizing and storing first and second x-ray picture information derived prior to and after, respectively, injection of a contrast medium into the subject. The first and second x-ray picture information are digitized, stored and processed to develop first and second processed picture data, respectively, and the first and second processed picture data are subtractively combined to produce picture data corresponding to a pictorial representation of differences between the x-ray picture information prior to and after, respectively, the injection of the contrast medium. The method and system call for various combinations of the following operations: averaging one or both of the x-ray picture data; convolution of the picture data derived prior to the injection of the contrast medium; pre-enhancement of one or both of the x-ray picture data; and post-enhancement of the picture data corresponding to the pictorial representation of the differences between the x-ray pictures prior to and after, respectively, the injection of the contrast medium. The inventive system includes a plurality of storage units and display units, in conjunction with an image processor, for rapidly operating on (whole-picture processing) the various x-ray picture data provided to the system.
Abstract:
A non-phosphorylated peptide or functionally equivalent composition binds to an SH2 domain of a signal transduction protein with high affinity. In particular, the composition binds to the SH2 domain with an affinity similar to that of at least one phosphorylated peptide that is a natural target for the protein. The inhibition of a signal transduction process can be accomplished by administering a non-phosphorylated peptide or functionally equivalent composition.
Abstract:
The present invention relates to a malaria chimeric peptide comprising a vaccinia virus system which expresses a protein corresponding substantially to the major merozoite surface antigen 1 (MSA1) of Plasmodium flaciparum or an immunogenic portion, thereof. In preferred embodiments, the MSA1 peptide is a 593 amino acid peptide corresponding to amino acids 1047 to 1640 of MSA1 and is combined with a signal peptide and/or an anchor peptide. Chimeric peptides having both signal and anchor sequences in combination with MSA1 sequences were the most effective in eliciting an immunogenic response from a vaccinated host.
Abstract:
A method of detecting an enzyme-mediated DNA cleavage reaction in a fluorometric assay is provided. The method can be used to detect DNA cleavage caused by restriction endonucleases, retroviral integrase enzymes, DNases, RNases, or enzymes utilized in other strand separating processes in molecular biology.
Abstract:
The invention relates generally to the quantitation of virus and viral nucleic acid. The invention relates to methods for quantitating an amount of virus present in a sample, comprising introducing into the sample a composition comprising a genetically tagged viral nucleic acid, isolating said wild type and said tagged nucleic acid, and quantitating said wild type and said tagged nucleic acid. The invention also relates to genetically tagged retroviral nucleic acid comprising a tag sequence, including insertions and deletions.
Abstract:
Methods and compositions are disclosed utilizing the optically pure (2R,4S) isomer of itraconazole. This compound is a potent drug for the treatment of local and systemic fungal, yeast, and dermatophyte infections, while avoiding the concomitant liability of adverse effects associated with the racemic mixture of itraconazole.
Abstract:
Methods and compositions are disclosed utilizing the optically pure (+) isomer of ketoconazole. This compound is a potent drug for the treatment of local and systemic fungal, yeast, and dermatophyte infections, while avoiding the concomitant liability of adverse effects associated with the racemic mixture of ketoconazole.
Abstract:
A dosimetry method, dosimeter and system characterized by the steps of storing information in a three dimensional optical memory element, then exposing the optical memory element to neutron or other high LET radiation to alter the information stored in the optical memory element as a function of the radiation to which the optical memory element is exposed, and then retrieving the altered information from the optical memory elements for subsequent analysis. The altered information is used to provide a measure of both the radiation dose and energy. In a preferred embodiment, the optical memory device of the dosimeter (18) is a 3-D ORAM (20) comprising a volume of a transparent polymer doped with a light sensitive chemical and, in particular, spirobenzopyran. The dosimeter (18) further has a holder (22) with a case (24) for the ORAM (20) and a carrier (26) for the case (24).
Abstract:
A pharmaceutical composition comprising the compound of formula (I) or a pharmaceutically acceptable salt thereof, for use in an anti-histaminic treatment which does not induce any significant cardiac arrhythmia, comprising administering a therapeutically effective amount of the compound of formula (I) to a human patient.
Abstract:
A method of preparing a liposomal anthracycline glycoside composition, which entails forming cardiolipin-containing liposomes by drying a lipid mixture containing cardiolipin, and then introducing an aqueous solution, and mixing the cardiolipin-containing liposomes with a solution of anthracycline glycoside.